The antidiabetics market size has grown rapidly in recent years. It will grow from $84.07 billion in 2025 to $93.29 billion in 2026 at a compound annual growth rate (CAGR) of 11%. The growth in the historic period can be attributed to rising global diabetes prevalence, increased availability of insulin therapies, expansion of oral antidiabetic medications, improved disease awareness and diagnosis, growth in healthcare access.
The antidiabetics market size is expected to see rapid growth in the next few years. It will grow to $141.48 billion in 2030 at a compound annual growth rate (CAGR) of 11%. The growth in the forecast period can be attributed to increasing adoption of next-generation diabetes drugs, rising focus on long-acting and once-weekly therapies, expansion of digital diabetes management integration, growing investments in metabolic disorder research, increasing demand for patient-centric treatment options. Major trends in the forecast period include increasing adoption of glp-1 and sglt2 therapies, rising focus on combination drug regimens, growing demand for personalized diabetes treatment, expansion of oral antidiabetic drug usage, enhanced emphasis on cardiovascular and weight benefits.
The increasing prevalence of lifestyle-related conditions is expected to drive the growth of the antidiabetics market in the coming years. Lifestyle-related conditions are health issues caused or worsened by behaviors such as unhealthy diet, lack of physical activity, smoking, and excessive alcohol consumption. The occurrence of these conditions is rising due to poor dietary habits, sedentary lifestyles, and higher stress levels. Antidiabetic medications aid in managing lifestyle-related conditions such as obesity and metabolic syndrome by enhancing insulin sensitivity and regulating blood glucose levels. For example, in August 2024, according to Statistics Canada, a Canada-based government agency, Canadian manufacturers produced 1.2 billion cigarettes in July 2024, representing a 4.3% increase from June 2024 and a 2.3% rise compared to July 2023. Consequently, the growing incidence of lifestyle-related conditions is fueling the expansion of the antidiabetic market.
Major companies operating in the antidiabetics market are focusing on developing advanced products, such as anti-diabetic biosimilars, to enhance glycemic control, lower the risk of cardiovascular complications, and provide more effective treatment options for patients with diabetes. An anti-diabetic biosimilar is a biologically similar medication to an already approved reference drug used in diabetes management, offering comparable safety, efficacy, and quality. For example, in January 2024, Glenmark Pharmaceuticals Limited, an India-based pharmaceutical company, introduced the first biosimilar of Liraglutide, an anti-diabetic drug. The Liraglutide biosimilar, launched under the name Lirafit, helps improve glycemic control in adults with type 2 diabetes mellitus. Clinical studies have demonstrated that it reduces glycemic parameters, supports weight loss, and enhances cardiovascular safety. As a GLP-1 receptor agonist, it stimulates glucose-dependent insulin secretion and suppresses inappropriate glucagon secretion. It is approved globally for the management of type 2 diabetes in adults.
In August 2023, Lupin, an India-based pharmaceutical company, acquired the brands ONDERO and ONDERO MET from Boehringer Ingelheim International GmbH for an undisclosed amount. Lupin’s acquisition of ONDERO and ONDERO MET is intended to strengthen its presence in the antidiabetic market and expand its product portfolio. Boehringer Ingelheim International GmbH is a Germany-based provider of antidiabetic medications.
Major companies operating in the antidiabetics market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Abbott Laboratories, Novartis AG, Takeda Pharmaceutical Company Limited, GSK plc, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Novo Nordisk A/S, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Sun Pharmaceutical Industries Limited, Cipla Limited, Dr. Reddy's Laboratories, Lupin Limited, Torrent Pharmaceuticals Ltd, Biocon Limited, Glenmark Pharmaceuticals Ltd.
North America was the largest region in the antidiabetics market in 2025. The regions covered in the antidiabetics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the antidiabetics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are influencing the antidiabetics market by increasing costs of imported active pharmaceutical ingredients, formulation excipients, delivery devices, and packaging materials used in insulin and oral antidiabetic production. Manufacturing and supply chains in North America and Europe are most affected due to dependence on globally sourced APIs, while Asia-Pacific faces pricing pressure on export-oriented pharmaceutical manufacturing. These tariffs are contributing to higher drug production costs and pricing pressures. However, they are also encouraging domestic API manufacturing, regional supply chain diversification, and investment in localized pharmaceutical production facilities.
The antidiabetics market research report is one of a series of new reports that provides antidiabetics market statistics, including antidiabetics industry global market size, regional shares, competitors with a antidiabetics market share, detailed antidiabetics market segments, market trends and opportunities, and any further data you may need to thrive in the antidiabetics industry. This antidiabetics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Antidiabetics are medications used to treat diabetes mellitus, a condition marked by elevated blood glucose levels. These drugs help regulate blood sugar in different ways, depending on the type of diabetes and the drug’s mechanism of action. Antidiabetics control blood sugar levels, minimize complications, improve overall health outcomes, enhance metabolic regulation and insulin sensitivity, provide personalized treatment options, and offer additional advantages such as weight management and cardiovascular protection.
The main drug classes of antidiabetics include insulin, GLP-1 receptor agonists, DPP-4 inhibitors, SGLT2 inhibitors, and others. Insulin is a hormone produced by the pancreas that helps control blood sugar levels. Diabetes is classified into type 1 and type 2, and the patient population comprises antidiabetics for pediatrics, antidiabetics for adults, and antidiabetics for geriatrics. Antidiabetics can be administered through insulin syringes or insulin pens, insulin pumps, intravenous infusion, oral administration, and other methods, and they are distributed through various channels such as online pharmacies, hospital pharmacies, and retail pharmacies.
The antidiabetics market consists of sales of pramlintide, thiazolidinediones, insulin glargine, and exenatide. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The antidiabetics market size is expected to see rapid growth in the next few years. It will grow to $141.48 billion in 2030 at a compound annual growth rate (CAGR) of 11%. The growth in the forecast period can be attributed to increasing adoption of next-generation diabetes drugs, rising focus on long-acting and once-weekly therapies, expansion of digital diabetes management integration, growing investments in metabolic disorder research, increasing demand for patient-centric treatment options. Major trends in the forecast period include increasing adoption of glp-1 and sglt2 therapies, rising focus on combination drug regimens, growing demand for personalized diabetes treatment, expansion of oral antidiabetic drug usage, enhanced emphasis on cardiovascular and weight benefits.
The increasing prevalence of lifestyle-related conditions is expected to drive the growth of the antidiabetics market in the coming years. Lifestyle-related conditions are health issues caused or worsened by behaviors such as unhealthy diet, lack of physical activity, smoking, and excessive alcohol consumption. The occurrence of these conditions is rising due to poor dietary habits, sedentary lifestyles, and higher stress levels. Antidiabetic medications aid in managing lifestyle-related conditions such as obesity and metabolic syndrome by enhancing insulin sensitivity and regulating blood glucose levels. For example, in August 2024, according to Statistics Canada, a Canada-based government agency, Canadian manufacturers produced 1.2 billion cigarettes in July 2024, representing a 4.3% increase from June 2024 and a 2.3% rise compared to July 2023. Consequently, the growing incidence of lifestyle-related conditions is fueling the expansion of the antidiabetic market.
Major companies operating in the antidiabetics market are focusing on developing advanced products, such as anti-diabetic biosimilars, to enhance glycemic control, lower the risk of cardiovascular complications, and provide more effective treatment options for patients with diabetes. An anti-diabetic biosimilar is a biologically similar medication to an already approved reference drug used in diabetes management, offering comparable safety, efficacy, and quality. For example, in January 2024, Glenmark Pharmaceuticals Limited, an India-based pharmaceutical company, introduced the first biosimilar of Liraglutide, an anti-diabetic drug. The Liraglutide biosimilar, launched under the name Lirafit, helps improve glycemic control in adults with type 2 diabetes mellitus. Clinical studies have demonstrated that it reduces glycemic parameters, supports weight loss, and enhances cardiovascular safety. As a GLP-1 receptor agonist, it stimulates glucose-dependent insulin secretion and suppresses inappropriate glucagon secretion. It is approved globally for the management of type 2 diabetes in adults.
In August 2023, Lupin, an India-based pharmaceutical company, acquired the brands ONDERO and ONDERO MET from Boehringer Ingelheim International GmbH for an undisclosed amount. Lupin’s acquisition of ONDERO and ONDERO MET is intended to strengthen its presence in the antidiabetic market and expand its product portfolio. Boehringer Ingelheim International GmbH is a Germany-based provider of antidiabetic medications.
Major companies operating in the antidiabetics market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Abbott Laboratories, Novartis AG, Takeda Pharmaceutical Company Limited, GSK plc, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Novo Nordisk A/S, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Sun Pharmaceutical Industries Limited, Cipla Limited, Dr. Reddy's Laboratories, Lupin Limited, Torrent Pharmaceuticals Ltd, Biocon Limited, Glenmark Pharmaceuticals Ltd.
North America was the largest region in the antidiabetics market in 2025. The regions covered in the antidiabetics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the antidiabetics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are influencing the antidiabetics market by increasing costs of imported active pharmaceutical ingredients, formulation excipients, delivery devices, and packaging materials used in insulin and oral antidiabetic production. Manufacturing and supply chains in North America and Europe are most affected due to dependence on globally sourced APIs, while Asia-Pacific faces pricing pressure on export-oriented pharmaceutical manufacturing. These tariffs are contributing to higher drug production costs and pricing pressures. However, they are also encouraging domestic API manufacturing, regional supply chain diversification, and investment in localized pharmaceutical production facilities.
The antidiabetics market research report is one of a series of new reports that provides antidiabetics market statistics, including antidiabetics industry global market size, regional shares, competitors with a antidiabetics market share, detailed antidiabetics market segments, market trends and opportunities, and any further data you may need to thrive in the antidiabetics industry. This antidiabetics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Antidiabetics are medications used to treat diabetes mellitus, a condition marked by elevated blood glucose levels. These drugs help regulate blood sugar in different ways, depending on the type of diabetes and the drug’s mechanism of action. Antidiabetics control blood sugar levels, minimize complications, improve overall health outcomes, enhance metabolic regulation and insulin sensitivity, provide personalized treatment options, and offer additional advantages such as weight management and cardiovascular protection.
The main drug classes of antidiabetics include insulin, GLP-1 receptor agonists, DPP-4 inhibitors, SGLT2 inhibitors, and others. Insulin is a hormone produced by the pancreas that helps control blood sugar levels. Diabetes is classified into type 1 and type 2, and the patient population comprises antidiabetics for pediatrics, antidiabetics for adults, and antidiabetics for geriatrics. Antidiabetics can be administered through insulin syringes or insulin pens, insulin pumps, intravenous infusion, oral administration, and other methods, and they are distributed through various channels such as online pharmacies, hospital pharmacies, and retail pharmacies.
The antidiabetics market consists of sales of pramlintide, thiazolidinediones, insulin glargine, and exenatide. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Antidiabetics Market Characteristics
3. Antidiabetics Market Supply Chain Analysis
4. Global Antidiabetics Market Trends and Strategies
5. Antidiabetics Market Analysis of End Use Industries
7. Global Antidiabetics Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Antidiabetics Total Addressable Market (TAM) Analysis for the Market
9. Antidiabetics Market Segmentation
10. Antidiabetics Market Regional and Country Analysis
11. Asia-Pacific Antidiabetics Market
12. China Antidiabetics Market
13. India Antidiabetics Market
14. Japan Antidiabetics Market
15. Australia Antidiabetics Market
16. Indonesia Antidiabetics Market
17. South Korea Antidiabetics Market
18. Taiwan Antidiabetics Market
19. South East Asia Antidiabetics Market
20. Western Europe Antidiabetics Market
21. UK Antidiabetics Market
22. Germany Antidiabetics Market
23. France Antidiabetics Market
24. Italy Antidiabetics Market
25. Spain Antidiabetics Market
26. Eastern Europe Antidiabetics Market
27. Russia Antidiabetics Market
28. North America Antidiabetics Market
29. USA Antidiabetics Market
30. Canada Antidiabetics Market
31. South America Antidiabetics Market
32. Brazil Antidiabetics Market
33. Middle East Antidiabetics Market
34. Africa Antidiabetics Market
36. Antidiabetics Market Competitive Landscape and Company Profiles
37. Antidiabetics Market Other Major and Innovative Companies
40. Antidiabetics Market High Potential Countries, Segments and Strategies
41. Appendix
Executive Summary
Antidiabetics Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses antidiabetics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for antidiabetics? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The antidiabetics market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Drug Class: Insulin; GLP-1 Receptor Agonists; DPP- 4 Inhibitors; SGLT2 Inhibitors; Other Drug Classes2) By Diabetes Type: Type 1; Type 2
3) By Patient Population: Antidiabetics For Pediatrics; Antidiabetics For Adults; Antidiabetics For Geriatrics
4) By Route Of Administration: Antidiabetics Administration Through Insulin Syringes Or Insulin Pens; Antidiabetics Administration Through Insulin Pumps; Intravenous Antidiabetics Infusion; Oral Antidiabetics Administration; Other Routes Of Antidiabetics Administration
5) By Distribution Channel: Online Pharmacies; Hospital Pharmacies; Retail Pharmacies
Subsegments:
1) By Insulin: Rapid-Acting Insulin; Short-Acting Insulin; Intermediate-Acting Insulin; Long-Acting Insulin; Premixed Insulin2) By GLP-1 Receptor Agonists: Exenatide; Liraglutide; Dulaglutide; Semaglutide; Lixisenatide
3) By DPP-4 Inhibitors: Sitagliptin; Saxagliptin; Linagliptin; Alogliptin
4) By SGLT2 Inhibitors: Canagliflozin; Dapagliflozin; Empagliflozin; Ertugliflozin
5) By Other Drug Classes: Sulfonylureas; Thiazolidinediones (TZDs); Alpha-Glucosidase Inhibitors; Meglitinides; GLP-1/Insulin Combination Therapy
Companies Mentioned: Pfizer Inc.; Johnson & Johnson; Merck & Co. Inc.; Sanofi S.A.; Bristol-Myers Squibb Company; AstraZeneca plc; Abbott Laboratories; Novartis AG; Takeda Pharmaceutical Company Limited; GSK plc; Eli Lilly and Company; Boehringer Ingelheim International GmbH; Novo Nordisk A/S; Teva Pharmaceutical Industries Ltd.; Astellas Pharma Inc.; Sun Pharmaceutical Industries Limited; Cipla Limited; Dr. Reddy's Laboratories; Lupin Limited; Torrent Pharmaceuticals Ltd; Biocon Limited; Glenmark Pharmaceuticals Ltd.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Antidiabetics market report include:- Pfizer Inc.
- Johnson & Johnson
- Merck & Co. Inc.
- Sanofi S.A.
- Bristol-Myers Squibb Company
- AstraZeneca plc
- Abbott Laboratories
- Novartis AG
- Takeda Pharmaceutical Company Limited
- GSK plc
- Eli Lilly and Company
- Boehringer Ingelheim International GmbH
- Novo Nordisk A/S
- Teva Pharmaceutical Industries Ltd.
- Astellas Pharma Inc.
- Sun Pharmaceutical Industries Limited
- Cipla Limited
- Dr. Reddy's Laboratories
- Lupin Limited
- Torrent Pharmaceuticals Ltd
- Biocon Limited
- Glenmark Pharmaceuticals Ltd.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 93.29 Billion |
| Forecasted Market Value ( USD | $ 141.48 Billion |
| Compound Annual Growth Rate | 11.0% |
| Regions Covered | Global |
| No. of Companies Mentioned | 23 |
